When the Trump administration introduced earlier this yr that it wouldn’t finalize a provision proposed by the Biden administration to broaden Medicare and Medicaid protection of GLP-1s, many advocates responded with deep disappointment.
However this month, the Trump administration unveiled its personal efforts to broaden entry to the favored weight reduction medicine, saying an settlement with GLP-1 producers Eli Lilly and Novo Nordisk. The settlement will permit sufferers to entry GLP-1s for considerably cheaper costs by means of TrumpRx, a government-run direct-to-consumer drug platform. It additionally reduces costs beneath Medicare and Medicaid, and allows Medicare to cowl GLP-1s for weight problems for the primary time.
Apart from placing a take care of the Trump administration, Eli Lilly can be charting a brand new course to broaden entry to GLP-1s. The corporate introduced plans on Friday to construct an employer-focused mannequin for weight problems administration drugs, which is able to embrace versatile profit design choices for weight problems administration care, a devoted pharmacy community and weight problems administration applications by means of third events. This may develop into out there in 2026.
Whereas many are applauding the Trump administration for taking this step to broaden entry to GLP-1s, some imagine that particularly focusing on weight reduction medicine truly does little or no to carry down total prescription drug prices.
“I believe that specializing in market options on GLP-1s alone misses the mark, as a result of it’s a market downside,” stated Chris Deacon, principal and founding father of VerSan Consulting. “[Whether it’s] GLP-1s or different drugs, now we have an issue of an entire lack of transparency for the purchaser.”
One other professional echoed these feedback, stating that whereas this can be a constructive transfer, there must be a broader effort with a purpose to successfully carry down drug prices completely.
“It is a step in the best path,” stated Edgar Asebey, an FDA regulatory legal professional at Frier Levitt. “A coverage initiative that’s extra of a blanket coverage with branded medicine could be a lot better for the American sufferers.”
What’s the Trump administration’s deal?
In keeping with a reality sheet, the Trump administration’s take care of Novo Nordisk and Eli Lilly has a number of parts, together with:
- Permitting shoppers to entry Ozempic and Wegovy for $350 when bought by means of TrumpRx, in comparison with the checklist worth of over $1,000
- Permitting shoppers to entry Zepbound and Orforglipron (if accredited) for $346 by means of TrumpRx, in comparison with the checklist worth of over $1,000
- If the FDA approves the Wegovy tablet, the preliminary dose might be out there at $150 per 30 days by means of TrumpRx
- Medicare costs for Ozempic, Wegovy, Mounjaro and Zepbound might be $245, and Medicare might be allowed to cowl Wegovy and Zepbound for weight problems for the primary time. Medicare beneficiaries can pay a co-pay of $50 per 30 days
- State Medicaid applications will even have entry to those costs for GLP-1s. States can at the moment determine whether or not to cowl weight problems medicine beneath Medicaid, and 13 states accomplish that, based on KFF
- Prices for different Eli Lilly and Novo Nordisk medicine will even be decreased when bought by means of TrumpRx, together with migraine remedy Emgality, diabetes treatment Trulicity and insulin merchandise NovoLog and Tresiba
What do the specialists assume?
Though the Trump administration’s deal lowers the costs of GLP-1s within the U.S., these costs are nonetheless considerably greater than in different international locations, famous Deacon of VerSan Consulting. For instance, the worth of Ozempic is $96 in Sweden, $93 within the U.Ok., $87 in Australia and $83 in France, based on KFF.
She added that with a purpose to make an precise distinction on prescription drug prices, the main focus shouldn’t solely be on GLP-1s.
“I believe staying centered on GLP-1s is a really sensible, tactical transfer by the business, as a result of it’s what individuals need,” she stated. “It appears like we’re shopping for off the American individuals and type of satisfying their want for reform within the pharmaceutical area by specializing in GLP-1s as a result of that’s what everyone’s speaking about, and that’s what so many individuals need. … In the meantime, it’s the complete type of chain throughout pharmaceutical buying that basically wants reform.”
Asebey of Frier Levitt agreed with this, stating {that a} main purpose different international locations have considerably decrease costs for GLP-1s is due to a single payer system. And whereas he believes this can be a nice first step, there are numerous different excessive price medicine that have to be lowered, like most cancers medicine.
“This isn’t actually as advantageous as if we had a single payer system, as a result of we don’t know … whether or not that is going to have an effect on well being plans beneath employers,” he stated. “Sure, non-public profit managers are negotiating these items, however that’s separate from what the White Home is doing proper now. That’s nonetheless a query mark. These aren’t the one medicine. These are the most well-liked ones, however different essential medicine are nonetheless very costly. What’s going to occur to them?”
The U.S. is much from transitioning to a single payer system. And within the absence of a single payer system, Asebey hopes that the administration continues to take comparable actions to decrease drug prices, even when it’s extra “piecemeal.”
He additionally made this suggestion:
“I believe it will be nice if the Trump administration introduced that there’s going to be the highest 40 branded medicine that come out yearly and to be added to a formulary that they may negotiate drug pricing. They’ve executed it with Novo Nordisk and with Lilly. Clearly, neither a type of corporations goes broke, they usually can afford to proceed accessing the U.S. market at very worthwhile worth factors. However I believe President Trump ought to use that bully pulpit for the nice of a larger variety of Individuals, not simply those that wish to drop pounds or are diabetic.”
It’s price noting that there have been a number of different makes an attempt to rein in drug prices. For instance, there are efforts to advance the 340B Drug Pricing Program, although some imagine this received’t repair this system’s points. Congress has additionally pursued PBM reforms, although these efforts have but to materialize.
Some steps have been launched to help employer-sponsored plans as properly, similar to Eli Lilly’s announcement on Friday to construct an employer-focused mannequin for weight administration medicine. Digital well being corporations Waltz Well being and 9amHealth additionally introduced employer fashions on Friday to broaden entry to Eli Lilly weight problems administration medicine. Nevertheless, these plans nonetheless goal weight reduction medicine particularly, versus addressing drug prices as an entire.
In the meantime, a prescription drug advocate stated that Trump’s GLP-1 deal is “life-changing” for many who are reliant on these medicine, however questioned the motives of drug corporations.
“Voluntary offers are depending on the ‘goodwill’ of corporations with a protracted historical past of exploiting their energy to maintain costs excessive on the expense of sufferers,” stated Merith Basey, govt director of Sufferers For Reasonably priced Medicine. “Eli Lilly and Novo Nordisk have moved in lockstep for years to lift insulin costs, so there’s actual concern that GLP-1 costs might rise once more simply as rapidly as they’ve been lowered. Producers alone set launch costs – and a transparent reminder of why we urgently want reforms that rein them in.”
Like Deacon and Asebey, Basey believes that there must be efforts past GLP-1s with a purpose to actually make a distinction. She argued that Medicare negotiation is at the moment the simplest software the U.S. has for decreasing drug prices and that this program needs to be expanded.
“Decrease costs for GLP-1s will assist many individuals, and we’re glad to see that progress. However fixing the prescription drug market – not only one class of medicines – requires structural reforms that guarantee all sufferers can entry the prescribed drugs they want at a worth they will afford,” she stated.
Photograph: Jason Dean, Getty Photographs